BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38-47. [PMID: 19942479 DOI: 10.1016/s1470-2045(09)70330-4] [Cited by in Crossref: 653] [Cited by in F6Publishing: 253] [Article Influence: 50.2] [Reference Citation Analysis]
Number Citing Articles
1 Karoui M, Rullier A, Luciani A, Bonnetain F, Auriault ML, Sarran A, Monges G, Trillaud H, Le Malicot K, Leroy K, Sobhani I, Bardier A, Moreau M, Brindel I, Seitz JF, Taieb J. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial. BMC Cancer 2015;15:511. [PMID: 26156156 DOI: 10.1186/s12885-015-1507-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
2 Liu C, Hu C, Huang J, Xiang K, Li Z, Qu J, Chen Y, Yang B, Qu X, Liu Y, Zhang G, Wen T. A Prognostic Nomogram of Colon Cancer With Liver Metastasis: A Study of the US SEER Database and a Chinese Cohort. Front Oncol 2021;11:591009. [PMID: 33738248 DOI: 10.3389/fonc.2021.591009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Cusano E, Wong C, Taguedong E, Vaska M, Abedin T, Nixon N, Karim S, Tang P, Heng DYC, Ezeife D. Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Curr Oncol 2021;28:4894-928. [PMID: 34898590 DOI: 10.3390/curroncol28060412] [Reference Citation Analysis]
4 Zdenkowski N, Chen S, van der Westhuizen A, Ackland S. Curative strategies for liver metastases from colorectal cancer: a review. Oncologist. 2012;17:201-211. [PMID: 22234631 DOI: 10.1634/theoncologist.2011-0300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
5 Molla M, Fernandez-Plana J, Albiol S, Fondevila C, Vollmer I, Cases C, Garcia-Criado A, Capdevila J, Conill C, Fundora Y, Fernandez-Martos C, Pineda E. Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT. J Clin Med 2021;10:2131. [PMID: 34069240 DOI: 10.3390/jcm10102131] [Reference Citation Analysis]
6 Deng Y; Chinese Southwest Oncology Group - the Committee of Colorectal Cancer. The "Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan (CPT-11), Oxaliplatin (LOHP), Continuous Infusion 5-Fluorouracil, and Leucovorin for Colorectal Cancer". Gastroenterol Rep (Oxf) 2021;9:279-89. [PMID: 34567559 DOI: 10.1093/gastro/goab033] [Reference Citation Analysis]
7 Bismuth H, Eshkenazy R, Arish A. Milestones in the evolution of hepatic surgery. Rambam Maimonides Med J 2011;2:e0021. [PMID: 23908793 DOI: 10.5041/RMMJ.10021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
8 Aigner F, Pratschke J, Schmelzle M. Oligometastatic Disease in Colorectal Cancer - How to Proceed?Visc Med. 2017;33:23-28. [PMID: 28612013 DOI: 10.1159/000454688] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
9 Pernot S, Pellerin O, Mineur L, Monterymard C, Smith D, Lapuyade B, Gallois C, Khemissa Akouz F, De Baere T, Tougeron D, Thirot-Bidault A, Audemar F, Simon M, Lecaille C, Louafi S, Lepage C, Ducreux M, Taieb J. Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. Dig Liver Dis 2022:S1590-8658(21)00898-7. [PMID: 35027324 DOI: 10.1016/j.dld.2021.12.012] [Reference Citation Analysis]
10 Fukami Y, Kaneoka Y, Maeda A, Takayama Y, Onoe S. Postoperative complications following aggressive repeat hepatectomy for colorectal liver metastasis have adverse oncological outcomes. Surg Today. 2017;47:99-107. [PMID: 27117689 DOI: 10.1007/s00595-016-1340-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
11 Pietrantonio F, Mazzaferro V, Miceli R, Cotsoglou C, Melotti F, Fanetti G, Perrone F, Biondani P, Muscarà C, Di Bartolomeo M, Coppa J, Maggi C, Milione M, Tamborini E, de Braud F. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Med Oncol 2015;32:182. [PMID: 26003673 DOI: 10.1007/s12032-015-0638-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
12 Symonds LK, Cohen SA. Use of perioperative chemotherapy in colorectal cancer metastatic to the liver. Gastroenterol Rep (Oxf) 2019;7:301-11. [PMID: 31687149 DOI: 10.1093/gastro/goz035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
13 Folprecht G, Bechstein WO. [Neoadjuvant therapy concepts for liver metastases]. Chirurg. 2011;82:989-994. [PMID: 22033894 DOI: 10.1007/s00104-011-2131-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Zheng B, Wang X, Wei M, Wang Q, Li J, Bi L, Deng X, Wang Z. First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer 2019;19:280. [PMID: 30922269 DOI: 10.1186/s12885-019-5481-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Binnebösel M, Lambertz A, Dejong K, Neumann UP. [Oligometastasized colorectal cancer-modern treatment strategies]. Chirurg 2018;89:497-504. [PMID: 29872867 DOI: 10.1007/s00104-018-0661-y] [Reference Citation Analysis]
16 Meng B, Folaron MR, Strawbridge RR, Sadeghipour N, Samkoe KS, Tichauer K, Davis SC. Noninvasive quantification of target availability during therapy using paired-agent fluorescence tomography. Theranostics 2020;10:11230-43. [PMID: 33042280 DOI: 10.7150/thno.45273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Eadens MJ, Grothey A. Curable metastatic colorectal cancer. Curr Oncol Rep. 2011;13:168-176. [PMID: 21298372 DOI: 10.1007/s11912-011-0157-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
18 Yao J, Huang A, Zheng X, Liu T, Lin Z, Zhang S, Yang Q, Zhang T, Ma H. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway. J Cancer Res Clin Oncol 2017;143:419-31. [PMID: 27838786 DOI: 10.1007/s00432-016-2302-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
19 Vogel A, Kirstein MM. First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials. Innov Surg Sci 2018;3:85-6. [PMID: 31579770 DOI: 10.1515/iss-2018-0012] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Lee SY, Oh SC. Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. Biomed Res Int. 2016;2016:7590245. [PMID: 27127793 DOI: 10.1155/2016/7590245] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
21 Hansdotter P, Scherman P, Petersen SH, Mikalonis M, Holmberg E, Rizell M, Naredi P, Syk I. Patterns and resectability of colorectal cancer recurrences: outcome study within the COLOFOL trial. BJS Open 2021;5:zrab067. [PMID: 34308474 DOI: 10.1093/bjsopen/zrab067] [Reference Citation Analysis]
22 Rosa B, de Jesus JP, de Mello EL, Cesar D, Correia MM. Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. Ecancermedicalscience 2015;9:582. [PMID: 26557880 DOI: 10.3332/ecancer.2015.582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
23 Franchi E, Donadon M, Torzilli G. Effects of volume on outcome in hepatobiliary surgery: a review with guidelines proposal. Glob Health Med 2020;2:292-7. [PMID: 33330823 DOI: 10.35772/ghm.2020.01013] [Reference Citation Analysis]
24 Stein A, Rüssel J, Peinert S, Arnold D. The role of peri-operative treatment in resectable liver metastases of colorectal cancer. Ther Adv Med Oncol 2010;2:389-98. [PMID: 21789150 DOI: 10.1177/1758834010375095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Bonadio RC, Amor Divino PH, Obando JSM, Lima KCA, Recchimuzzi DZ, Kruger JAP, Saragiotto DF, Capareli FC, Hoff PM. Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings. J Glob Oncol. 2019;5:1-6. [PMID: 31479339 DOI: 10.1200/jgo.19.00180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Zhu YJ, Chen Y, Hu HY, Zhou YW, Zhu YT, Liu JY. Predictive Risk Factors and Online Nomograms for Synchronous Colon Cancer With Liver Metastasis. Front Oncol 2020;10:1681. [PMID: 33123459 DOI: 10.3389/fonc.2020.01681] [Reference Citation Analysis]
27 Xu J, Qin X, Wang J, Zhang S, Zhong Y, Ren L, Wei Y, Zeng S, Wan D, Zheng S; Society of Surgery; Chinese Medical Association; Committee of Colorectal Cancer, Chinese Anti-cancer Association. Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol. 2011;137:1379-1396. [PMID: 21796415 DOI: 10.1007/s00432-011-0999-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
28 Takamoto T, Hashimoto T, Miyata A, Shimada K, Maruyama Y, Makuuchi M. Repeat Hepatectomy After Major Hepatectomy for Colorectal Liver Metastases. J Gastrointest Surg 2020;24:380-7. [PMID: 30830515 DOI: 10.1007/s11605-019-04154-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
29 Aranda E, Abad A, Carrato A, Cervantes A, García-Foncillas J, García Alfonso P, García Carbonero R, Gómez España A, Tabernero JM, Díaz-Rubio E. Treatment recommendations for metastatic colorectal cancer. Clin Transl Oncol 2011;13:162-78. [PMID: 21421461 DOI: 10.1007/s12094-011-0636-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
30 Heinrich S, Watzka F, Lang H. Integrative Concepts for Liver Surgery. Visc Med 2020;36:351-8. [PMID: 33178731 DOI: 10.1159/000511043] [Reference Citation Analysis]
31 Torres-Jiménez J, Esteban-Villarrubia J, Ferreiro-Monteagudo R, Carrato A. Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist. Cancers (Basel) 2021;13:5938. [PMID: 34885047 DOI: 10.3390/cancers13235938] [Reference Citation Analysis]
32 Lee KH, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Chao Y, Teng HW. The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon. Br J Cancer 2021;125:816-25. [PMID: 34188197 DOI: 10.1038/s41416-021-01470-2] [Reference Citation Analysis]
33 Elshenawy MA, Badran A, Aljubran A, Alzahrani A, Rauf MS, Eldali A, Bazarbashi S. Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer. World J Surg Oncol 2020;18:163. [PMID: 32641137 DOI: 10.1186/s12957-020-01930-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Jiang D, Li X, Wang H, Shi Y, Xu C, Lu S, Huang J, Xu Y, Zeng H, Su J, Hou Y, Tan L. The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma. BMC Cancer 2015;15:377. [PMID: 25953424 DOI: 10.1186/s12885-015-1393-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
35 Costi R, Leonardi F, Zanoni D, Violi V, Roncoroni L. Palliative care and end-stage colorectal cancer management: The surgeon meets the oncologist. World J Gastroenterol 2014; 20(24): 7602-7621 [PMID: 24976699 DOI: 10.3748/wjg.v20.i24.7602] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
36 Yasuno M, Uetake H, Ishiguro M, Mizunuma N, Komori T, Miyata G, Shiomi A, Kagimura T, Sugihara K. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival. Int J Clin Oncol 2019;24:516-25. [PMID: 30612267 DOI: 10.1007/s10147-018-01393-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
37 Haraldsdottir S, Bekaii-Saab T. Integrating anti-EGFR therapies in metastatic colorectal cancer. J Gastrointest Oncol. 2013;4:285-298. [PMID: 23997940 DOI: 10.3978/j.issn.2078-6891.2013.028] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
38 Mohammad WM, Martel G, Mimeault R, Fairfull-Smith RJ, Auer RC, Balaa FK. Evaluating agreement regarding the resectability of colorectal liver metastases: a national case-based survey of hepatic surgeons. HPB (Oxford). 2012;14:291-297. [PMID: 22487066 DOI: 10.1111/j.1477-2574.2012.00440.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
39 Dattatreya S. Metastatic colorectal cancer-prolonging overall survival with targeted therapies. South Asian J Cancer 2013;2:179-85. [PMID: 24455615 DOI: 10.4103/2278-330X.114152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
40 Uemura M, Kim HM, Hata T, Sakata K, Okuyama M, Takemoto H, Fujii H, Fukuzaki T, Morita T, Hata T, Takemasa I, Satoh T, Mizushima T, Doki Y, Mori M; Multi-Center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer. Mol Clin Oncol 2016;5:375-9. [PMID: 27446583 DOI: 10.3892/mco.2016.938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
41 Evrard S, Poston G, Kissmeyer-Nielsen P, Diallo A, Desolneux G, Brouste V, Lalet C, Mortensen F, Stättner S, Fenwick S, Malik H, Konstantinidis I, DeMatteo R, D'Angelica M, Allen P, Jarnagin W, Mathoulin-Pelissier S, Fong Y. Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS One 2014;9:e114404. [PMID: 25485541 DOI: 10.1371/journal.pone.0114404] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
42 Meriggi F, Bertocchi P, Zaniboni A. Management of potentially resectable colorectal cancer liver metastases. World J Gastrointest Surg 2013; 5(5): 138-145 [PMID: 23710291 DOI: 10.4240/wjgs.v5.i5.138] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
43 Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012;30:4566-4572. [PMID: 23150701 DOI: 10.1200/jco.2012.45.2854] [Cited by in Crossref: 138] [Cited by in F6Publishing: 58] [Article Influence: 13.8] [Reference Citation Analysis]
44 Rossi L, Zullo A, Zoratto F, Papa A, Strudel M, Colonna M, Tomao S. Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. Oncol Rev 2012;6:e6. [PMID: 25992208 DOI: 10.4081/oncol.2012.e6] [Reference Citation Analysis]
45 Jeyarajah DR, Doyle MBM, Espat NJ, Hansen PD, Iannitti DA, Kim J, Thambi-Pillai T, Visser BC. Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm. J Gastrointest Oncol 2020;11:443-60. [PMID: 32399284 DOI: 10.21037/jgo.2020.01.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
46 Chen D, Zhang X, Gao G, Shen L, Xie J, Qian X, Wang H. Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis. World J Surg Oncol 2018;16:200. [PMID: 30296945 DOI: 10.1186/s12957-018-1502-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
47 Kobayashi A, Kaido T, Hamaguchi Y, Okumura S, Shirai H, Kamo N, Yagi S, Taura K, Okajima H, Uemoto S. Impact of Visceral Adiposity as Well as Sarcopenic Factors on Outcomes in Patients Undergoing Liver Resection for Colorectal Liver Metastases. World J Surg 2018;42:1180-91. [PMID: 28936708 DOI: 10.1007/s00268-017-4255-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
48 Settmacher U, Scheuerlein H, Rauchfuss F. [Assessment of resectability of colorectal liver metastases and extended resection]. Chirurg 2014;85:24-30. [PMID: 24317339 DOI: 10.1007/s00104-013-2566-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Cetin B, Bilgetekin I, Cengiz M, Ozet A. Managing Synchronous Liver Metastases in Colorectal Cancer. Indian J Surg Oncol 2018;9:461-71. [PMID: 30538373 DOI: 10.1007/s13193-018-0765-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Mitchell D, Puckett Y, Nguyen QN. Literature Review of Current Management of Colorectal Liver Metastasis. Cureus. 2019;11:e3940. [PMID: 30937238 DOI: 10.7759/cureus.3940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
51 Oki E, Ando K, Nakanishi R, Sugiyama M, Nakashima Y, Kubo N, Kudou K, Saeki H, Nozoe T, Emi Y, Maehara Y. Recent advances in treatment for colorectal liver metastasis. Ann Gastroenterol Surg 2018;2:167-75. [PMID: 29863162 DOI: 10.1002/ags3.12071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
52 Kataoka K, Kanazawa A, Iwamoto S, Kato T, Nakajima A, Arimoto A. Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease? World J Surg 2014;38:936-46. [PMID: 24166026 DOI: 10.1007/s00268-013-2305-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
53 Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, Vennarecci G, Mottolese M, Sperduti I, Cognetti F. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010;103:1542-1547. [PMID: 20959822 DOI: 10.1038/sj.bjc.6605940] [Cited by in Crossref: 119] [Cited by in F6Publishing: 113] [Article Influence: 9.9] [Reference Citation Analysis]
54 Coimbra FJ, Ribeiro HS, Marques MC, Herman P, Chojniak R, Kalil AN, Wiermann EG, Cavallero SR, Coelho FF, Fernandes PH, Silvestrini AA, Almeida MF, de Araújo AL, Pitombo M, Teixeira HM, Waechter FL, Ferreira FG, Diniz AL, D'Ippolito G, D'Ippolito G, Begnami MD, Prolla G, Balzan SM, de Oliveira TB, Szultan LA, Lendoire J, Torres OJ. FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATION. Arq Bras Cir Dig 2015;28:222-30. [PMID: 26734788 DOI: 10.1590/S0102-6720201500040002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
55 Stein A, Schmoll HJ. Systemic treatment of liver metastases from colorectal cancer. Ther Adv Med Oncol. 2013;5:193-203. [PMID: 23634197 DOI: 10.1177/1758834012473347] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
56 Haraldsdottir S, Wu C, Bloomston M, Goldberg RM. What is the optimal neo-adjuvant treatment for liver metastasis? Ther Adv Med Oncol. 2013;5:221-234. [PMID: 23858331 DOI: 10.1177/1758834013485111] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
57 Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist. 2011;16:1557-1564. [PMID: 22016477 DOI: 10.1634/theoncologist.2011-0141] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
58 Faris JE, Ryan DP. Biomarker-Driven Therapy in the Neoadjuvant Treatment of Colorectal Liver Metastases. Curr Colorectal Cancer Rep 2012;8:143-51. [DOI: 10.1007/s11888-012-0123-8] [Reference Citation Analysis]
59 Xu J, Fan J, Qin X, Cai J, Gu J, Wang S, Wang X, Zhang S, Zhang Z; China CRLM Guideline Group. Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018). J Cancer Res Clin Oncol. 2019;145:725-736. [PMID: 30542791 DOI: 10.1007/s00432-018-2795-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
60 Parmar KL, O'Reilly D, Valle JW, Braun M, Naish JH, Williams SR, Lloyd WK, Malcomson L, Cresswell K, Bamford C, Renehan AG. Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study. BMJ Open 2020;10:e027630. [PMID: 32967864 DOI: 10.1136/bmjopen-2018-027630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K. Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer. PLoS One 2012;7:e50806. [PMID: 23226389 DOI: 10.1371/journal.pone.0050806] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
62 Schmoll H, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde C, Balmana J, Regula J, Nagtegaal I, Beets-tan R, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne C, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard J, El Ghazaly H, Gallardo J, Garin A, Glynne-jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals of Oncology 2012;23:2479-516. [DOI: 10.1093/annonc/mds236] [78495111110.1093/annonc/mds236','', '1948-5204')">Reference Citation Analysis]
63 Lowes M, Kleiss M, Lueck R, Detken S, Koenig A, Nietert M, Beissbarth T, Stanek K, Langer C, Ghadimi M, Conradi LC, Homayounfar K. The utilization of multidisciplinary tumor boards (MDT) in clinical routine: results of a health care research study focusing on patients with metastasized colorectal cancer. Int J Colorectal Dis 2017;32:1463-9. [PMID: 28779354 DOI: 10.1007/s00384-017-2871-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
64 Sunakawa Y, Izawa N, Mizukami T, Horie Y, Hirakawa M, Arai H, Ogura T, Tsuda T, Nakajima TE. Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy. Onco Targets Ther 2017;10:4599-605. [PMID: 28979148 DOI: 10.2147/OTT.S106101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
65 De Stefano A, Carlomagno C. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9732-9743 [PMID: 25110411 DOI: 10.3748/wjg.v20.i29.9732] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
66 Umeda Y, Nagasaka T, Takagi K, Yoshida R, Yoshida K, Fuji T, Matsuda T, Yasui K, Kumano K, Sato H, Yagi T, Fujiwara T. Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases. Langenbecks Arch Surg 2021. [PMID: 34839388 DOI: 10.1007/s00423-021-02373-9] [Reference Citation Analysis]
67 Saxena A, Bester L, Shan L, Perera M, Gibbs P, Meteling B, Morris DL. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. J Cancer Res Clin Oncol. 2014;140:537-547. [PMID: 24318568 DOI: 10.1007/s00432-013-1564-4] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
68 Frank M, Mittendorf T. Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review. Pharmacoeconomics 2013;31:215-28. [PMID: 23338963 DOI: 10.1007/s40273-012-0017-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
69 Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamata H, Koisumi J. Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer. Surg Today 2013;43:1088-94. [PMID: 23143145 DOI: 10.1007/s00595-012-0416-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
70 Cremolini C, Milione M, Marmorino F, Morano F, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, de Braud F, Mazzaferro V, Falcone A, Pietrantonio F. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. Br J Cancer. 2018;118:955-965. [PMID: 29531324 DOI: 10.1038/s41416-018-0015-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
71 Kawaguchi Y, De Bellis M, Panettieri E, Duwe G, Vauthey JN. Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments. Surg Oncol Clin N Am 2021;30:205-18. [PMID: 33220806 DOI: 10.1016/j.soc.2020.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Folprecht G. [Current medicinal treatment of metastasized colorectal carcinoma]. Chirurg. 2010;81:507-515. [PMID: 20574792 DOI: 10.1007/s00104-010-1892-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
73 Kawagoe S, Nakano M, Uchino K, Arimizu K, Kajitani T, Shimokawa H, Kusumoto T, Ikejiri K, Baba E. Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer. Mol Clin Oncol 2019;11:243-51. [PMID: 31396385 DOI: 10.3892/mco.2019.1894] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, Maiello E. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. 2011;16:228-238. [PMID: 21273511 DOI: 10.1634/theoncologist.2010-0298] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 6.6] [Reference Citation Analysis]
75 Ismaili N. Treatment of colorectal liver metastases. World J Surg Oncol. 2011;9:154. [PMID: 22115124 DOI: 10.1186/1477-7819-9-154] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
76 Idrees K, Safar B, Hawkins WG. Unresectable Colorectal Cancer Synchronous Metastases: How to Manage the Primary Tumor. Curr Colorectal Cancer Rep 2012;8:118-22. [DOI: 10.1007/s11888-012-0125-6] [Reference Citation Analysis]
77 Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010;10:567. [PMID: 20958992 DOI: 10.1186/1471-2407-10-567] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
78 Muro K, Itabashi M, Hashida H, Masuishi T, Bando H, Denda T, Yamanaka T, Ohashi Y, Sugihara K. Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial. Jpn J Clin Oncol 2019;49:339-46. [PMID: 30753571 DOI: 10.1093/jjco/hyy189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
79 Heinrich S, Lang H. Hepatic resection for primary and secondary liver malignancies. Innov Surg Sci 2017;2:1-8. [PMID: 31579727 DOI: 10.1515/iss-2017-0009] [Reference Citation Analysis]
80 Lam VW, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford) 2013;15:483-91. [PMID: 23750490 DOI: 10.1111/j.1477-2574.2012.00607.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 102] [Article Influence: 11.9] [Reference Citation Analysis]
81 Geredeli C, Yasar N. FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. World J Surg Oncol 2018;16:67. [PMID: 29587749 DOI: 10.1186/s12957-018-1359-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Hirose K, Oki E, Shimose T, Sakamoto S, Sasaki S, Jogo T, Hu Q, Tsuda Y, Ando K, Nakashima Y, Saeki H, Mori M. Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials. Int J Clin Oncol 2019;24:1397-405. [PMID: 31332611 DOI: 10.1007/s10147-019-01509-8] [Reference Citation Analysis]
83 Dunne DF, Jones RP, Malik HZ, Fenwick SW, Poston GJ. Surgical management of colorectal liver metastases: a European perspective. Hepat Oncol. 2014;1:121-133. [PMID: 30190946 DOI: 10.2217/hep.13.3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
84 Peloso A, Franchi E, Canepa MC, Barbieri L, Briani L, Ferrario J, Bianco C, Quaretti P, Brugnatelli S, Dionigi P. Combined use of intraoperative ultrasound and indocyanine green fluorescence imaging to detect liver metastases from colorectal cancer. HPB (Oxford). 2013;15:928-934. [PMID: 23458105 DOI: 10.1111/hpb.12057] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 6.7] [Reference Citation Analysis]
85 Toyama Y, Ushigome T, Watanabe K, Kitamura H, Onda S, Saito R, Yoshida S, Kawahara H, Yanagisawa S, Yanaga K. Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report. World J Surg Oncol 2012;10:129. [PMID: 22747970 DOI: 10.1186/1477-7819-10-129] [Reference Citation Analysis]
86 Shen Y, Yang J, Xu Z, Gu DY, Chen JF. Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: A meta-analysis. World J Gastroenterol 2012; 18(21): 2712-2718 [PMID: 22690082 DOI: 10.3748/wjg.v18.i21.2712] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
87 Personeni N, Torzilli G, Santoro A. Advanced colorectal liver metastases and surgery after preoperative chemotherapy: is response-based selection enough? J Clin Oncol 2011;29:2733-4; author reply 2734-5. [PMID: 21606418 DOI: 10.1200/JCO.2011.35.9976] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
88 Matsuhashi N, Takahashi T, Matsui S, Tanahashi T, Imai H, Tanaka Y, Yamaguchi K, Yoshida K. A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. Int J Oncol 2018;52:1391-400. [PMID: 29568913 DOI: 10.3892/ijo.2018.4322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
89 Rossi L, Vakiarou F, Zoratto F, Bianchi L, Papa A, Basso E, Verrico M, Lo Russo G, Evangelista S, Rinaldi G, Perrone-Congedi F, Spinelli GP, Stati V, Caruso D, Prete A, Tomao S. Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Manag Res. 2013;5:377-385. [PMID: 24399885 DOI: 10.2147/cmar.s47986] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
90 Tasoudis PT, Ziogas IA, Alexopoulos SP, Fung JJ, Tsoulfas G. Role of liver transplantation in the management of colorectal liver metastases: Challenges and opportunities. World J Clin Oncol 2021; 12(12): 1193-1201 [DOI: 10.5306/wjco.v12.i12.1193] [Reference Citation Analysis]
91 Primavesi F, Fadinger N, Biggel S, Braunwarth E, Gasser E, Sprung S, Göbel G, Gassner E, Stättner S, Öfner D. Early response evaluation during preoperative chemotherapy for colorectal liver metastases: Combined size and morphology-based criteria predict pathological response and survival after resection. J Surg Oncol 2019. [PMID: 31788797 DOI: 10.1002/jso.25796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
92 Liang YH, Shao YY, Chen JY, Liang PC, Cheng AL, Lin ZZ. Modern prospection for hepatic arterial infusion chemotherapy in malignancies with liver metastases. Int J Hepatol 2013;2013:141590. [PMID: 23691329 DOI: 10.1155/2013/141590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
93 Saxena A, Chua TC, Chu FC, Ng KM, Herle P, Morris DL. Impact of treatment modality and number of lesions on recurrence and survival outcomes after treatment of colorectal cancer liver metastases. J Gastrointest Oncol 2014;5:46-56. [PMID: 24490042 DOI: 10.3978/j.issn.2078-6891.2013.055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Nieuwenhuizen S, Puijk RS, van den Bemd B, Aldrighetti L, Arntz M, van den Boezem PB, Bruynzeel AME, Burgmans MC, de Cobelli F, Coolsen MME, Dejong CHC, Derks S, Diederik A, van Duijvendijk P, Eker HH, Engelsman AF, Erdmann JI, Fütterer JJ, Geboers B, Groot G, Haasbeek CJA, Janssen JJ, de Jong KP, Kater GM, Kazemier G, Kruimer JWH, Leclercq WKG, van der Leij C, Manusama ER, Meier MAJ, van der Meijs BB, Melenhorst MCAM, Nielsen K, Nijkamp MW, Potters FH, Prevoo W, Rietema FJ, Ruarus AH, Ruiter SJS, Schouten EAC, Serafino GP, Sietses C, Swijnenburg RJ, Timmer FEF, Versteeg KS, Vink T, de Vries JJJ, de Wilt JHW, Zonderhuis BM, Scheffer HJ, van den Tol PMP, Meijerink MR. Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group.Cancers (Basel). 2020;12. [PMID: 32635230 DOI: 10.3390/cancers12071779] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
95 Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, Chao G, Wallin J, Tabernero J. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. Br J Cancer 2016;114:372-80. [PMID: 26766738 DOI: 10.1038/bjc.2015.480] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
96 Pavel MC, Casanova R, Estalella L, Memba R, Llàcer-Millán E, Achalandabaso M, Julià E, Geoghegan J, Jorba R. The effect of preoperative chemotherapy on liver regeneration after portal vein embolization/ligation or liver resection in patients with colorectal liver metastasis: a systematic review protocol. Syst Rev 2020;9:279. [PMID: 33276812 DOI: 10.1186/s13643-020-01545-w] [Reference Citation Analysis]
97 Nanashima A, Takeshita H, Abo T, Tou K, Tanaka K, Fukuda D, Kunizaki M, Hidaka S, Sawai T. Recent advances and significance of intra-arterial infusion chemotherapy in non-resectable colorectal liver metastasis. J Gastrointest Oncol 2013;4:164-72. [PMID: 23730512 DOI: 10.3978/j.issn.2078-6891.2013.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien P. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol 2020;17:755-72. [DOI: 10.1038/s41575-020-0314-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
99 Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, Kopetz S, Loyer EM, Curley SA, Abdalla EK, Vauthey JN. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 2013;257:1079-88. [PMID: 23426338 DOI: 10.1097/SLA.0b013e318283a4d1] [Cited by in Crossref: 125] [Cited by in F6Publishing: 56] [Article Influence: 13.9] [Reference Citation Analysis]
100 Kumar N, Duncan T, O'Reilly D, Káposztás Z, Parry C, Rees J, Junnarkar S. Partial ALPPS with a longer wait between procedures is safe and yields adequate future liver remnant hypertrophy. Ann Hepatobiliary Pancreat Surg 2019;23:13-9. [PMID: 30863803 DOI: 10.14701/ahbps.2019.23.1.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Assenat E. FOLFIRINOX for the treatment of colorectal cancer: latest evidence from clinical trials. Colorectal Cancer 2012;1:181-4. [DOI: 10.2217/crc.12.20] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
102 Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol 2017;18:e653-706. [PMID: 29208398 DOI: 10.1016/S1470-2045(17)30698-8] [Cited by in Crossref: 83] [Cited by in F6Publishing: 35] [Article Influence: 16.6] [Reference Citation Analysis]
103 Kishi Y, Shimada K, Nara S, Esaki M, Kosuge T. Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma. World J Hepatol 2014; 6(12): 836-843 [PMID: 25544870 DOI: 10.4254/wjh.v6.i12.836] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
104 Utsunomiya S, Uehara K, Kurimoto T, Hirose K, Fukaya M, Takahashi Y, Taguchi Y, Itatsu K, Nagino M. Synchronous rectal and esophageal cancer treated with chemotherapy followed by two-stage resection. World J Clin Cases 2013; 1(2): 87-91 [PMID: 24303474 DOI: 10.12998/wjcc.v1.i2.87] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 Katayose Y, Unno M. Management of liver metastases from colorectal cancer. Clin J Gastroenterol 2010;3:128-35. [PMID: 26190118 DOI: 10.1007/s12328-010-0155-z] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
106 Rebersek M, Boc M, Cerkovnik P, Benedik J, Hlebanja Z, Volk N, Novakovic S, Ocvirk J. Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis. Radiol Oncol 2011;45:285-91. [PMID: 22933967 DOI: 10.2478/v10019-011-0039-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
107 Garlipp B, Bruns CJ. The evidence for resection post-selective internal radiation therapy. Future Oncol 2014;10:49-52. [PMID: 25478767 DOI: 10.2217/fon.14.223] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Folprecht G, Van Cutsem E, Ducreux M, Nordlinger B; European Organisation for Research and Treatment of Cancer (EORTC); Gastro-Intestinal Tract Cancer Group; Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst. 2017;109. [PMID: 28376151 DOI: 10.1093/jnci/djx015] [Cited by in Crossref: 197] [Cited by in F6Publishing: 192] [Article Influence: 39.4] [Reference Citation Analysis]
109 Basso M, Dadduzio V, Ardito F, Lombardi P, Strippoli A, Vellone M, Orlandi A, Rossi S, Cerchiaro E, Cassano A, Giuliante F, Barone C. Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab. Medicine (Baltimore) 2016;95:e3722. [PMID: 27196492 DOI: 10.1097/MD.0000000000003722] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
110 Sobani ZA, Sawant A, Jafri M, Correa AK, Sahin IH. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. World J Clin Oncol 2016; 7(5): 340-351 [PMID: 27777877 DOI: 10.5306/wjco.v7.i5.340] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
111 Bertolini F, Malavasi N, Scarabelli L, Fiocchi F, Bagni B, Del Giovane C, Colucci G, Gerunda GE, Depenni R, Zironi S, Fontana A, Pettorelli E, Luppi G, Conte PF. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer 2011;104:1079-84. [PMID: 21386839 DOI: 10.1038/bjc.2011.43] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
112 van Kessel CS, Buckens CF, van den Bosch MA, van Leeuwen MS, van Hillegersberg R, Verkooijen HM. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol. 2012;19:2805-2813. [PMID: 22396005 DOI: 10.1245/s10434-012-2300-z] [Cited by in Crossref: 109] [Cited by in F6Publishing: 82] [Article Influence: 10.9] [Reference Citation Analysis]
113 Lou E, D'Souza D, Nelson AC. Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab. J Natl Compr Canc Netw. 2017;15:427-432. [PMID: 28404754 DOI: 10.6004/jnccn.2017.0043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
114 Peeters M, Price T, Taieb J, Geissler M, Rivera F, Canon JL, Pentheroudakis G, Koukakis R, Burdon P, Siena S. Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. Br J Cancer. 2018;119:303-312. [PMID: 30013091 DOI: 10.1038/s41416-018-0165-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
115 Sirohi B, Shrikhande SV, Perakath B, Raghunandharao D, Julka PK, Lele V, Chaturvedi A, Nandakumar A, Ramadwar M, Bhatia V, Mittal R, Kaur T, Shukla DK, Rath GK. Indian Council of Medical Research consensus document for the management of colorectal cancer. Indian J Med Paediatr Oncol 2014;35:192-6. [PMID: 25336788 DOI: 10.4103/0971-5851.142031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
116 Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, Alexander DD, Choti MA, Poston G. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283-301. [PMID: 23152705 DOI: 10.2147/clep.s34285] [Cited by in Crossref: 67] [Cited by in F6Publishing: 154] [Article Influence: 6.7] [Reference Citation Analysis]
117 Takemura N, Saiura A, Koga R, Arita J, Yoshioka R, Ono Y, Hiki N, Sano T, Yamamoto J, Kokudo N, Yamaguchi T. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg 2012;397:951-7. [PMID: 22615045 DOI: 10.1007/s00423-012-0959-z] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 8.3] [Reference Citation Analysis]
118 Perrakis A, Juratli TA, Hohenberger W, Croner RS, Schackert G. [Surgery for metastases, anatomical and ethical limits. Special aspect: oligometastases]. Chirurg 2016;87:208-15. [PMID: 26857002 DOI: 10.1007/s00104-015-0147-0] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
119 Bruera G, Cannita K, Di Giacomo D, Lamy A, Frébourg T, Sabourin JC, Tosi M, Alesse E, Ficorella C, Ricevuto E. Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). BMC Med 2013;11:59. [PMID: 23497191 DOI: 10.1186/1741-7015-11-59] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
120 Cripps C, Gill S, Ahmed S, Colwell B, Dowden S, Kennecke H, Maroun J, Samson B, Thirlwell M, Wong R. Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer. Curr Oncol 2010;17:39-45. [PMID: 21151408 DOI: 10.3747/co.v17i6.670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
121 Wang Y, Zhang GY, Xu LC, He XH, Huang HZ, Li GD, Wang YH, Wang GZ, Li WT. Clinical Outcomes and Predictors in Patients With Unresectable Colorectal Cancer Liver Metastases Following Salvage Percutaneous Radiofrequency Ablation: A Single Center Preliminary Experience. Technol Cancer Res Treat 2020;19:1533033820963662. [PMID: 33034276 DOI: 10.1177/1533033820963662] [Reference Citation Analysis]
122 Bertolini F, Malavasi N, Scarabelli L, Fiocchi F, Bagni B, Del Giovane C, Colucci G, Gerunda GE, Depenni R, Zironi S. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer. 2011;104:1079-1084. [PMID: 21386839 DOI: 10.1038/bjc.2011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Ciombor KK, Goldberg RM. Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer. Hepat Oncol 2014;1:331-45. [PMID: 30190967 DOI: 10.2217/hep.14.13] [Reference Citation Analysis]
124 Ninomiya M, Emi Y, Motomura T, Tomino T, Iguchi T, Kayashima H, Harada N, Uchiyama H, Nishizaki T, Higashi H, Kuwano H. Efficacy of neoadjuvant chemotherapy in patients with high-risk resectable colorectal liver metastases. Int J Clin Oncol 2021;26:2255-64. [PMID: 34519930 DOI: 10.1007/s10147-021-02024-5] [Reference Citation Analysis]
125 Kim CW, Lee JL, Yoon YS, Park IJ, Lim SB, Yu CS, Kim TW, Kim JC. Resection after preoperative chemotherapy versus synchronous liver resection of colorectal cancer liver metastases: A propensity score matching analysis. Medicine (Baltimore) 2017;96:e6174. [PMID: 28207557 DOI: 10.1097/MD.0000000000006174] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
126 Lee HY, Woo IS. Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates. Cancers (Basel) 2021;13:4590. [PMID: 34572817 DOI: 10.3390/cancers13184590] [Reference Citation Analysis]
127 Sakai N, Furukawa K, Takayashiki T, Kuboki S, Takano S, Ohtsuka M. Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases. BMC Cancer 2021;21:412. [PMID: 33858364 DOI: 10.1186/s12885-021-08144-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Stein A, Bokemeyer C. How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol 2014; 20(4): 899-907 [PMID: 24574764 DOI: 10.3748/wjg.v20.i4.899] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
129 Cai GX, Cai SJ. Multi-modality treatment of colorectal liver metastases. World J Gastroenterol 2012; 18(1): 16-24 [PMID: 22228966 DOI: 10.3748/wjg.v18.i1.16] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
130 Kawamura J, Yazawa T, Sumida K, Kida Y, Ogawa R, Tani M, Kawasoe J, Yamamoto M, Harada H, Yamamoto H, Zaima M. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases. World J Surg Oncol 2016;14:56. [PMID: 26911142 DOI: 10.1186/s12957-016-0807-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
131 Wang Y, Fang MZ, Jin HY. Recent advances in epidermal growth factor receptor-targeted therapy of colorectal cancer. Shijie Huaren Xiaohua Zazhi 2010; 18(17): 1804-1809 [DOI: 10.11569/wcjd.v18.i17.1804] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Spelt L, Ansari D, Swanling M, Holka P, Andersson R. Parenchyma-sparing hepatectomy (PSH) versus non-PSH for bilobar liver metastases of colorectal cancer. Ann Gastroenterol 2018;31:115-20. [PMID: 29333076 DOI: 10.20524/aog.2017.0205] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
133 Konishi T, Yoshidome H, Shimizu H, Yoshitomi H, Furukawa K, Takayashiki T, Kuboki S, Takano S, Miyazaki M, Ohtsuka M. Splenic enlargement induced by preoperative chemotherapy is a useful indicator for predicting liver regeneration after resection for colorectal liver metastases. World J Surg Oncol 2020;18:139. [PMID: 32576191 DOI: 10.1186/s12957-020-01918-4] [Reference Citation Analysis]
134 Zimmitti G, Shindoh J, Mise Y, Kopetz S, Loyer EM, Andreou A, Cooper AB, Kaur H, Aloia TA, Maru DM, Vauthey JN. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol. 2015;22:834-842. [PMID: 25227306 DOI: 10.1245/s10434-014-4042-6] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
135 Chua TC, Bester L, Saxena A, Morris DL. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol 2011;137:865-73. [PMID: 20859640 DOI: 10.1007/s00432-010-0948-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
136 Sasaki K, Margonis GA, Andreatos N, Wilson A, Gani F, Amini N, Pawlik TM. Pre-hepatectomy carcinoembryonic antigen (CEA) levels among patients undergoing resection of colorectal liver metastases: do CEA levels still have prognostic implications? HPB (Oxford) 2016;18:1000-9. [PMID: 27769662 DOI: 10.1016/j.hpb.2016.09.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
137 Khan K, Wale A, Brown G, Chau I. Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone? World J Gastroenterol 2014; 20(35): 12391-12406 [PMID: 25253940 DOI: 10.3748/wjg.v20.i35.12391] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
138 Kassahun WT. Unresolved issues and controversies surrounding the management of colorectal cancer liver metastasis. World J Surg Oncol 2015;13:61. [PMID: 25890279 DOI: 10.1186/s12957-014-0420-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
139 García-Alfonso P, Salazar R, García-Foncillas J, Musulén E, García-Carbonero R, Payá A, Pérez-Segura P, Ramón y Cajal S, Navarro S; Spanish Society of Medical Oncology (SEOM)., Spanish Society of Pathology (SEAP). Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol 2012;14:726-39. [PMID: 22855150 DOI: 10.1007/s12094-012-0856-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
140 Passot G, Chun YS, Kopetz SE, Overman MJ, Conrad C, Aloia TA, Vauthey JN. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. Eur J Surg Oncol 2016;42:1378-84. [PMID: 27358198 DOI: 10.1016/j.ejso.2016.02.249] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
141 Tomizawa K, Miura Y, Fukui Y, Hanaoka Y, Toda S, Moriyama J, Inoshita N, Ozaki Y, Takano T, Matoba S, Kuroyanagi H. Curative resection for locally advanced sigmoid colon cancer using neoadjuvant chemotherapy with FOLFOX plus panitumumab: A case report. Int J Surg Case Rep 2017;31:128-31. [PMID: 28135678 DOI: 10.1016/j.ijscr.2017.01.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
142 Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouché O, Ychou M, Bensadoun RJ, Dreno B, André T. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist 2012;17:555-68. [PMID: 22426526 DOI: 10.1634/theoncologist.2011-0365] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
143 Shiomi A, Kusuhara M, Sugino T, Sugiura T, Ohshima K, Nagashima T, Urakami K, Serizawa M, Saya H, Yamaguchi K. Comprehensive genomic analysis contrasting primary colorectal cancer and matched liver metastases. Oncol Lett 2021;21:466. [PMID: 33907576 DOI: 10.3892/ol.2021.12727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Wu B, Yang JK, Zhu YJ. Conversion therapy for colorectal cancer patients with potentially resectable liver metastases. Shijie Huaren Xiaohua Zazhi 2014; 22(4): 533-540 [DOI: 10.11569/wcjd.v22.i4.533] [Reference Citation Analysis]
145 Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow H, Duckworth A, Heister P, Praseedom R, Jah A, Balakrishnan A, Harper S, Liau S, Kosmoliaptsis V, Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol 2020; 11(10): 761-808 [PMID: 33200074 DOI: 10.5306/wjco.v11.i10.761] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
146 Karanicolas PJ, Metrakos P, Chan K, Asmis T, Chen E, Kingham TP, Kemeny N, Porter G, Fields RC, Pingpank J. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. Curr Oncol. 2014;21:e129-e136. [PMID: 24523610 DOI: 10.3747/co.21.1577] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
147 Devaud N, Kanji ZS, Dhani N, Grant RC, Shoushtari H, Serrano PE, Nanji S, Greig PD, McGilvray I, Moulton CA, Wei A, Gallinger S, Cleary SP. Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases. HPB (Oxford) 2014;16:475-80. [PMID: 23927606 DOI: 10.1111/hpb.12159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
148 Folprecht G, Weitz J, Hoffmann RT. [Computed tomographic morphological evaluation of neoadjuvant chemotherapy. Effectiveness of the therapy for colorectal liver metastases]. Chirurg 2014;85:31-6. [PMID: 24366286 DOI: 10.1007/s00104-013-2563-3] [Reference Citation Analysis]
149 Lang H, Baumgart J, Roth W, Moehler M, Kloth M. Cancer gene related characterization of patterns and point of recurrence after resection of colorectal liver metastases. Ann Transl Med 2021;9:1372. [PMID: 34733924 DOI: 10.21037/atm-21-292] [Reference Citation Analysis]
150 Li Y, Wang J, Gao X, Han W, Zheng Y, Xu H, Zhang C, He Q, Zhang L, Li Z. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation. PLoS One. 2014;9:e113186. [PMID: 25427200 DOI: 10.1371/journal.pone.0113186] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
151 Faron M, Chirica M, Tranchard H, Balladur P, de Gramont A, Afchain P, Andre T, Paye F. Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis. J Gastrointest Cancer 2014;45:298-306. [PMID: 24610400 DOI: 10.1007/s12029-014-9594-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
152 Ferrero A, Langella S, Russolillo N, Vigano’ L, Lo Tesoriere R, Capussotti L. Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease. J Gastrointest Surg. 2012;16:806-814. [PMID: 22258869 DOI: 10.1007/s11605-011-1810-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
153 García-Alfonso P, Ferrer A, Gil S, Dueñas R, Pérez MT, Molina R, Capdevila J, Safont MJ, Castañón C, Cano JM, Lara R. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Target Oncol 2015;10:453-65. [PMID: 25752908 DOI: 10.1007/s11523-015-0362-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
154 Wen F, Li Q. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. World J Gastroenterol 2016; 22(23): 5332-5341 [PMID: 27340349 DOI: 10.3748/wjg.v22.i23.5332] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
155 Somashekhar SP, Ashwin KR, Zaveri SS, Rauthan A, Patil P. Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab. Indian J Surg Oncol 2016;7:11-7. [PMID: 27065676 DOI: 10.1007/s13193-015-0442-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
156 Bachet JB, Paoletti X, Fournier L, Rougier P. [What is the contribution of tumor response in colorectal cancer?]. Bull Cancer 2013;100:743-55. [PMID: 23831844 DOI: 10.1684/bdc.2013.1780] [Reference Citation Analysis]
157 Kanat O. Current treatment options for patients with initially unresectable isolated colorectal liver metastases. World J Clin Oncol 2016; 7(1): 9-14 [PMID: 26862487 DOI: 10.5306/wjco.v7.i1.9] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
158 Passot G, Soubrane O, Giuliante F, Zimmitti G, Goéré D, Yamashita S, Vauthey JN. Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases. Liver Cancer 2016;6:72-9. [PMID: 27995091 DOI: 10.1159/000449349] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
159 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
160 Snyder A, Kemeny N, Shamseddine A, Al-Olayan A, El-Merhi F, Kelsen DP, Jamali F, Sidani M, Mukherji D, El-Naghy M, O'Reilly EM, Saltz LB, Abou-Alfa GK. Liver-directed conversion therapy in metastatic colon cancer. J Gastrointest Oncol 2015;6:322-8. [PMID: 26029460 DOI: 10.3978/j.issn.2078-6891.2015.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Jones C, Taylor MA, McWilliams B. The role of cetuximab as first-line treatment of colorectal liver metastases. HPB (Oxford) 2013;15:11-7. [PMID: 23216774 DOI: 10.1111/j.1477-2574.2012.00591.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
162 Moorcraft SY, Smyth EC, Cunningham D. The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therap Adv Gastroenterol 2013;6:381-95. [PMID: 24003339 DOI: 10.1177/1756283X13491797] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
163 Egeland C, Rostved AA, Schultz NA, Pommergaard HC, Daugaard TR, Thøfner LB, Rasmussen A, Hillingsø JG. Morbidity and mortality after liver surgery for colorectal liver metastases: a cohort study in a high-volume fast-track programme. BMC Surg 2021;21:312. [PMID: 34261457 DOI: 10.1186/s12893-021-01301-4] [Reference Citation Analysis]
164 Ribeiro HS, Torres OJ, Marques MC, Herman P, Kalil AN, Fernandes Ede S, Oliveira FF, Castro Ldos S, Hanriot R, Oliveira SC, Boff MF, Costa WL Jr, Gil Rde A, Pfiffer TE, Makdissi FF, Rocha Mde S, Amaral PC, Costa LA, Aloia TA. I BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 2: APPROACH TO RESECTABLE METASTASES. Arq Bras Cir Dig 2016;29:9-13. [PMID: 27120731 DOI: 10.1590/0102-6720201600010003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
165 Modest DP, Heinemann V, Folprecht G, Denecke T, Pratschke J, Lang H, Bemelmans M, Becker T, Rentsch M, Seehofer D, Bruns CJ, Gebauer B, Held S, Stahler A, Heinrich K, von Einem JC, Stintzing S, Neumann UP, Ricard I. Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. Ann Surg Oncol 2020;27:2389-401. [PMID: 32172334 DOI: 10.1245/s10434-020-08219-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
166 Koucky K, Wein A, Konturek PC, Albrecht H, Reulbach U, Männlein G, Wolff K, Ostermeier N, Busse D, Golcher H, Schildberg C, Janka R, Hohenberger W, Hahn EG, Siebler J, Neurath MF, Boxberger F. Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing. Med Sci Monit 2011;17:CR248-58. [PMID: 21525806 DOI: 10.12659/msm.881764] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
167 Matsuishi K, Miyamoto Y, Hiyoshi Y, Tokunaga R, Imai K, Hayashi H, Yamashita Y, Yoshida N, Baba H. Ongoing 5-year+ survival after multiple metastasectomies, followed by CAPOX plus bevacizumab, for metastatic colorectal cancer. Surg Case Rep 2020;6:149. [PMID: 32588352 DOI: 10.1186/s40792-020-00913-x] [Reference Citation Analysis]
168 Dede K, Mersich T, Besznyák I, Zaránd A, Salamon F, Baranyai ZS, Landherr L, Jakab F, Bursics A. Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment. Pathol Oncol Res. 2013;19:501-508. [PMID: 23420304 DOI: 10.1007/s12253-013-9608-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
169 Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer 2011;117:4484-92. [PMID: 21446046 DOI: 10.1002/cncr.26036] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
170 Torzilli G, Viganò L, Giuliante F, Pinna AD. Liver surgery in Italy. Criteria to identify the hospital units and the tertiary referral centers entitled to perform it. Updates Surg 2016;68:135-42. [PMID: 27294278 DOI: 10.1007/s13304-016-0373-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
171 Osterlund P, Salminen T, Soveri LM, Kallio R, Kellokumpu I, Lamminmäki A, Halonen P, Ristamäki R, Lantto E, Uutela A, Osterlund E, Ovissi A, Nordin A, Heervä E, Lehtomäki K, Räsänen J, Murashev M, Aroviita L, Jekunen A, Lindvall-Andersson R, Nyandoto P, Kononen J, Lepistö A, Poussa T, Muhonen T, Ålgars A, Isoniemi H; Members of The RAXO study group are collaborators of this study and are listed in Appendix Table 4B. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study. Lancet Reg Health Eur 2021;3:100049. [PMID: 34557799 DOI: 10.1016/j.lanepe.2021.100049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
172 Hur H, Kim NK, Kim HG, Min BS, Lee KY, Shin SJ, Cheon JH, Choi SH. Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis. Br J Cancer. 2012;106:53-60. [PMID: 22068817 DOI: 10.1038/bjc.2011.469] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
173 Tang B, Li Q, Xiao Y, Sivaloganathan S. A novel hybrid model of tumor control, combining pulse surveillance with tumor size-guided therapies. Applied Mathematical Modelling 2022;104:259-78. [DOI: 10.1016/j.apm.2021.11.025] [Reference Citation Analysis]
174 Heinrich S, Lang H. [Neoadjuvant chemotherapy or primary surgery for colorectal liver metastases. Pro primary surgery]. Chirurg 2014;85:17-23. [PMID: 24337153 DOI: 10.1007/s00104-013-2565-1] [Cited by in Crossref: 6] [Article Influence: 0.7] [Reference Citation Analysis]
175 Barone C, Pinto C, Normanno N, Capussotti L, Cognetti F, Falcone A, Mantovani L. KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting. PLoS One. 2014;9:e85897. [PMID: 24465771 DOI: 10.1371/journal.pone.0085897] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
176 Rahbari NN, D'Angelica MI. Surgical salvage of recurrence after resection of colorectal liver metastases: incidence and outcomes. Hepat Oncol 2017. [PMID: 28768424 DOI: 10.2217/hep-2017-0002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
177 Borie F, Dubray V, Tretarre B. Impact of recommendations and new therapies on the prognosis of colon cancer with synchronous liver metastasis. Clin Res Hepatol Gastroenterol 2021;:101856. [PMID: 34963650 DOI: 10.1016/j.clinre.2021.101856] [Reference Citation Analysis]
178 Homayounfar K, Bleckmann A, Conradi LC, Sprenger T, Lorf T, Niessner M, Sahlmann CO, Meller J, Liersch T, Ghadimi BM. Metastatic recurrence after complete resection of colorectal liver metastases: impact of surgery and chemotherapy on survival. Int J Colorectal Dis 2013;28:1009-17. [PMID: 23371333 DOI: 10.1007/s00384-013-1648-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
179 Giessen C, Fischer von Weikersthal L, Laubender RP, Stintzing S, Modest DP, Schalhorn A, Schulz C, Heinemann V. Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial. Br J Cancer 2013;109:1428-36. [PMID: 23963138 DOI: 10.1038/bjc.2013.475] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
180 Schimanski CC, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Heinemann V, Geißler M, Schulz-Abelius A, Bernhard H, Schön MR, Greil R, Galle P, Lang H, Schmidtmann I, Moehler M. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). Oncoimmunology 2020;9:1806680. [PMID: 32923171 DOI: 10.1080/2162402X.2020.1806680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
181 Wittel UA, Lubgan D, Ghadimi M, Belyaev O, Uhl W, Bechstein WO, Grützmann R, Hohenberger WM, Schmid A, Jacobasch L, Croner RS, Reinacher-Schick A, Hopt UT, Pirkl A, Oettle H, Fietkau R, Golcher H. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. BMC Cancer 2019;19:979. [PMID: 31640628 DOI: 10.1186/s12885-019-6148-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
182 Akhtar R, Chandel S, Sarotra P, Medhi B. Current status of pharmacological treatment of colorectal cancer. World J Gastrointest Oncol 2014; 6(6): 177-183 [PMID: 24936228 DOI: 10.4251/wjgo.v6.i6.177] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
183 Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y, Li W, Xu N, Lin LZ, Wu Q, Li Y, Yang J, Pan H, Ouyang X, Qiu W, Wu K, Xiong J, Dai G, Liang H, Hu C, Zhang J, Tao M, Yao Q, Wang J, Chen J, Eggleton SP, Liu T. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. J Clin Oncol 2018;36:3031-9. [PMID: 30199311 DOI: 10.1200/JCO.2018.78.3183] [Cited by in Crossref: 64] [Cited by in F6Publishing: 32] [Article Influence: 16.0] [Reference Citation Analysis]
184 Conradi LC, Spitzner M, Metzger AL, Kisly M, Middel P, Bohnenberger H, Gaedcke J, Ghadimi MB, Liersch T, Rüschoff J, Beißbarth T, König A, Grade M. Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer. BMC Cancer 2019;19:880. [PMID: 31488078 DOI: 10.1186/s12885-019-6051-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Glynne-Jones R, Kronfli M. Locally advanced rectal cancer: a comparison of management strategies. Drugs. 2011;71:1153-1177. [PMID: 21711061 DOI: 10.2165/11591330-000000000-00000] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
186 Hacker U, Hallek M, Kubicka S. [Multimodality therapy of colorectal cancer]. Internist (Berl) 2010;51:1366-73. [PMID: 20967408 DOI: 10.1007/s00108-010-2671-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
187 Fiorentini G, Sarti D, Aliberti C, Carandina R, Mambrini A, Guadagni S. Multidisciplinary approach of colorectal cancer liver metastases. World J Clin Oncol 2017; 8(3): 190-202 [PMID: 28638789 DOI: 10.5306/wjco.v8.i3.190] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
188 Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Segelov E. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS One. 2015;10:e0135599. [PMID: 26275292 DOI: 10.1371/journal.pone.0135599] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
189 Oki E, Emi Y, Yamanaka T, Uetake H, Muro K, Takahashi T, Nagasaka T, Hatano E, Ojima H, Manaka D, Kusumoto T, Katayose Y, Fujiwara T, Yoshida K, Unno M, Hyodo I, Tomita N, Sugihara K, Maehara Y. Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial). Br J Cancer 2019;121:222-9. [PMID: 31285591 DOI: 10.1038/s41416-019-0518-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
190 Sunakawa Y, Schirripa M, Lenz HJ. Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. Crit Rev Oncol Hematol 2016;100:117-26. [PMID: 26850575 DOI: 10.1016/j.critrevonc.2016.01.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
191 Ichikawa N, Kamiyama T, Yokoo H, Homma S, Maeda Y, Shinohara T, Tsuruga Y, Kazui K, Iijima H, Yoshida T, Taketomi A. Preoperative chemotherapy in colorectal cancer patients with synchronous liver metastasis. Mol Clin Oncol 2020;12:374-83. [PMID: 32190322 DOI: 10.3892/mco.2020.1992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Recondo GJ, Díaz-Cantón E, de la Vega M, Greco M, Recondo GS, Valsecchi ME. Advances and new perspectives in the treatment of metastatic colon cancer. World J Gastrointest Oncol 2014; 6(7): 211-224 [PMID: 25024813 DOI: 10.4251/wjgo.v6.i7.211] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
193 Di Carlo S, Yeung D, Mills J, Zaitoun A, Cameron I, Gomez D. Resection margin influences the outcome of patients with bilobar colorectal liver metastases. World J Hepatol 2016; 8(34): 1502-1510 [PMID: 28008341 DOI: 10.4254/wjh.v8.i34.1502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
194 Czauderna C, Luley K, von Bubnoff N, Marquardt JU. Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. Int J Mol Sci 2021;22:11780. [PMID: 34769209 DOI: 10.3390/ijms222111780] [Reference Citation Analysis]
195 Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810. [PMID: 25369977 DOI: 10.1186/1471-2407-14-810] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 10.3] [Reference Citation Analysis]
196 Taieb J, Rivera F, Siena S, Karthaus M, Valladares-Ayerbes M, Gallego J, Geissler M, Koukakis R, Demonty G, Peeters M. Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. J Cancer Res Clin Oncol. 2018;144:321-335. [PMID: 29080924 DOI: 10.1007/s00432-017-2534-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
197 Nasti G, Piccirillo MC, Izzo F, Ottaiano A, Albino V, Delrio P, Romano C, Giordano P, Lastoria S, Caracò C. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer. 2013;108:1566-1570. [PMID: 23558891 DOI: 10.1038/bjc.2013.140] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
198 Huiskens J, van Gulik TM, van Lienden KP, Engelbrecht MR, Meijer GA, van Grieken NC, Schriek J, Keijser A, Mol L, Molenaar IQ, Verhoef C, de Jong KP, Dejong KH, Kazemier G, Ruers TM, de Wilt JH, van Tinteren H, Punt CJ. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer 2015;15:365. [PMID: 25943574 DOI: 10.1186/s12885-015-1323-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
199 Iwamoto S, Maeda H, Hazama S, Oba K, Okayama N, Suehiro Y, Yamasaki T, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N. Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer. J Cancer 2018;9:4092-8. [PMID: 30519308 DOI: 10.7150/jca.26840] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
200 Hu H, Wang K, Huang M, Kang L, Wang W, Wang H, Qiu M, Lin R, Zhang H, Lan P, Wu X, Liu G, Wan Y, Liu M, Zhou Z, Huang Y, Li F, Zhang J, Cai Y, Ma T, Zhou J, Wang H, Ling J, Cai Y, Wu Z, Luo S, Ling L, Deng Y. Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial. Oncologist 2021;26:e90-8. [PMID: 33400355 DOI: 10.1634/theoncologist.2020-0563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
201 Glynne-Jones R, Hadaki M, Harrison M. The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. J Gastrointest Oncol 2013;4:264-84. [PMID: 23997939 DOI: 10.3978/j.issn.2078-6891.2013.037] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
202 Nakai T, Okuno K, Kitaguchi H, Ishikawa H, Yamasaki M. Unresectable colorectal liver metastases: the safety and efficacy of conversion therapy using hepatic arterial infusion immunochemotherapy with 5-fluorouracil and polyethylene glycol-interferon α-2a. World J Surg 2013;37:1919-26. [PMID: 23564218 DOI: 10.1007/s00268-013-2043-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
203 Kobayashi A, Miyagawa S. Advances in therapeutics for liver metastasis from colorectal cancer. World J Gastrointest Oncol 2010; 2(10): 380-389 [PMID: 21160889 DOI: 10.4251/wjgo.v2.i10.380] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
204 Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2011;26:823-833. [PMID: 21286919 DOI: 10.1007/s00384-011-1149-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
205 Gur I, Diggs BS, Wagner JA, Vaccaro GM, Lopez CD, Sheppard BC, Orloff SL, Billingsley KG. Safety and outcomes following resection of colorectal liver metastases in the era of current perioperative chemotherapy. J Gastrointest Surg 2013;17:2133-42. [PMID: 24091909 DOI: 10.1007/s11605-013-2295-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
206 Kataoka K, Kanazawa A, Nakajima A, Yamaguchi A, Arimoto A, Kohno Y. Feasibility and potential benefit of preoperative chemotherapy for colorectal liver metastasis (CLM): a single-centered retrospective study. Surg Today 2013;43:1154-61. [PMID: 23139049 DOI: 10.1007/s00595-012-0410-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
207 Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(15): 4208-4219 [PMID: 24764659 DOI: 10.3748/wjg.v20.i15.4208] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
208 Vera R, González-Flores E, Rubio C, Urbano J, Valero Camps M, Ciampi-Dopazo JJ, Orcajo Rincón J, Morillo Macías V, Gomez Braco MA, Suarez-Artacho G. Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM.Clin Transl Oncol. 2020;22:647-662. [PMID: 31359336 DOI: 10.1007/s12094-019-02182-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
209 Baba K, Oshita A, Kohyama M, Inoue S, Kuroo Y, Yamaguchi T, Nakamura H, Sugiyama Y, Tazaki T, Sasaki M, Imamura Y, Daimaru Y, Ohdan H, Nakamitsu A. Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis. World J Gastroenterol 2015; 21(6): 1982-1988 [PMID: 25684967 DOI: 10.3748/wjg.v21.i6.1982] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
210 Wang JX, Wu HL, Zhu M, Zhou R. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials. Pathol Oncol Res 2020;26:159-66. [PMID: 29383654 DOI: 10.1007/s12253-017-0365-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
211 Bai L, Wang F, Li ZZ, Ren C, Zhang DS, Zhao Q, Lu YX, Wang DS, Ju HQ, Qiu MZ, Wang ZQ, Wang FH, Xu RH. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis. Medicine (Baltimore) 2016;95:e4531. [PMID: 28002313 DOI: 10.1097/MD.0000000000004531] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
212 Bredt LC, Rachid AF. Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis. World J Surg Oncol. 2014;12:391. [PMID: 25528650 DOI: 10.1186/1477-7819-12-391] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
213 Wang CC, Li J. An update on chemotherapy of colorectal liver metastases. World J Gastroenterol 2012; 18(1): 25-33 [PMID: 22228967 DOI: 10.3748/wjg.v18.i1.25] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
214 Elferink MA, de Jong KP, Klaase JM, Siemerink EJ, de Wilt JH. Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands. Int J Colorectal Dis. 2015;30:205-212. [PMID: 25503801 DOI: 10.1007/s00384-014-2085-6] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 11.1] [Reference Citation Analysis]
215 Wei F, Shin D, Cai X. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. Int J Clin Oncol 2018;23:443-51. [PMID: 29289981 DOI: 10.1007/s10147-017-1231-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
216 Siriwardena AK, Mason JM, Mullamitha S, Hancock HC, Jegatheeswaran S. Management of colorectal cancer presenting with synchronous liver metastases. Nat Rev Clin Oncol 2014;11:446-59. [DOI: 10.1038/nrclinonc.2014.90] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 9.4] [Reference Citation Analysis]
217 Volk AM, Fritzmann J, Reissfelder C, Weber GF, Weitz J, Rahbari NN. Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases. BMC Cancer 2016;16:84. [PMID: 26864935 DOI: 10.1186/s12885-016-2095-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
218 Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, Xu RH. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J Gastroenterol 2010; 16(46): 5881-5888 [PMID: 21155011 DOI: 10.3748/wjg.v16.i46.5881] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
219 Bednarsch J, Jara M, Lock JF, Malinowski M, Pratschke J, Stockmann M. Noninvasive diagnosis of chemotherapy induced liver injury by LiMAx test--two case reports and a review of the literature. BMC Res Notes 2015;8:99. [PMID: 25889706 DOI: 10.1186/s13104-015-1055-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
220 Shiomi K, Naito M, Sato T, Nakamura T, Nakashima H, Naito M, Mikubo M, Matsui Y, Watanabe M, Satoh Y. Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer. Ann Med Surg (Lond) 2017;20:19-25. [PMID: 28702182 DOI: 10.1016/j.amsu.2017.06.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
221 Mise Y, Hasegawa K, Saiura A, Oba M, Yamamoto J, Nomura Y, Takayama T, Hashiguchi Y, Shibasaki M, Sakamoto H, Yamagata S, Aoyanagi N, Kaneko H, Koyama H, Miyagawa S, Shinozaki E, Yoshida S, Nozawa H, Kokudo N. A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO Trial). Ann Surg Oncol 2020;27:4188-95. [PMID: 32514802 DOI: 10.1245/s10434-020-08627-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
222 Turley MC, Moore C, Creasy JM, Sharib J, Lan B, Thacker JKM, Migaly J, Zani S, Allen PJ, Mantyh CR, Lidsky ME. Combined Primary Resection with Hepatic Artery Infusion Pump Implantation Is Safe for Unresectable Colorectal Liver Metastases. J Gastrointest Surg 2021. [PMID: 34820727 DOI: 10.1007/s11605-021-05195-8] [Reference Citation Analysis]
223 Semrad TJ, Fahrni AR, Gong IY, Khatri VP. Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings. Ann Surg Oncol 2015;22 Suppl 3:S855-62. [PMID: 26100816 DOI: 10.1245/s10434-015-4610-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
224 D'Angelica MI, Correa-Gallego C, Paty PB, Cercek A, Gewirtz AN, Chou JF, Capanu M, Kingham TP, Fong Y, DeMatteo RP. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261:353-360. [PMID: 24646562 DOI: 10.1097/sla.0000000000000614] [Cited by in Crossref: 101] [Cited by in F6Publishing: 34] [Article Influence: 14.4] [Reference Citation Analysis]
225 Khan K, Athauda A, Aitken K, Cunningham D, Watkins D, Starling N, Cook GJ, Kalaitzaki E, Chau I, Rao S. Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. Oncologist 2016;21:1502-8. [PMID: 27742904 DOI: 10.1634/theoncologist.2016-0222] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
226 Modest DP, Neumann UP, Pratschke J. FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity? Eur J Cancer 2017;73:71-3. [PMID: 28081915 DOI: 10.1016/j.ejca.2016.12.005] [Reference Citation Analysis]
227 Yashiro M, Qiu H, Hasegawa T, Zhang X, Matsuzaki T, Hirakawa K. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells. Br J Cancer. 2011;105:1522-1532. [PMID: 21997136 DOI: 10.1038/bjc.2011.397] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
228 Choti MA. Liver-directed treatments for metastatic colorectal cancer. Curr Treat Options Oncol 2014;15:456-64. [PMID: 24952016 DOI: 10.1007/s11864-014-0297-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
229 Kogawa T, Doi A, Shimokawa M, Fouad TM, Osuga T, Tamura F, Mizushima T, Kimura T, Abe S, Ihara H, Kukitsu T, Sumiyoshi T, Yoshizaki N, Hirayama M, Sasaki T, Kawarada Y, Kitashiro S, Okushiba S, Kondo H, Tsuji Y. Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer. Target Oncol 2015;10:125-33. [PMID: 24859798 DOI: 10.1007/s11523-014-0322-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
230 Ruzzenente A, Conci S, Iacono C, Valdegamberi A, Campagnaro T, Bertuzzo F, Bagante F, De Angelis M, Guglielmi A. Usefulness of contrast-enhanced intraoperative ultrasonography (CE-IOUS) in patients with colorectal liver metastases after preoperative chemotherapy. J Gastrointest Surg. 2013;17:281-287. [PMID: 23065500 DOI: 10.1007/s11605-012-2043-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
231 Gül-Klein S, Schmuck R, Modest DP, Pratschke J. [Treatment of colorectal and non-colorectal liver metastases: rationale for neoadjuvant therapeutic concepts]. Chirurg 2020;91:396-404. [PMID: 32291472 DOI: 10.1007/s00104-020-01133-7] [Reference Citation Analysis]
232 Pereyra D, Rumpf B, Ammann M, Perrodin SF, Tamandl D, Haselmann C, Stift J, Brostjan C, Laengle F, Beldi G, Gruenberger T, Starlinger P. The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy. Ann Surg Oncol 2019;26:791-9. [PMID: 30617869 DOI: 10.1245/s10434-018-07125-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
233 Chan G, Chee CE. Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer. Cancers (Basel) 2020;12:E3535. [PMID: 33256170 DOI: 10.3390/cancers12123535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
234 Stavrou GA, Ghamarnejad O, Oldhafer KJ. Warum werden zu wenige Patienten mit kolorektalen Lebermetastasen zur Resektion vorgestellt? Chirurg 2021;92:736-41. [DOI: 10.1007/s00104-021-01363-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Sato O, Tsuchikawa T, Yamada T, Sato D, Nakanishi Y, Asano T, Noji T, Yo K, Ebihara Y, Murakami S, Nakamura T, Okamura K, Shichinohe T, Mitsuhashi T, Hirano S. Metastatic mixed adenoneuroendocrine carcinoma of the liver successfully resected by hepatic trisectionectomy following chemotherapy: A case report. Clin Case Rep. 2019;7:491-496. [PMID: 30899479 DOI: 10.1002/ccr3.1968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
236 Schreckenbach T, Malkomes P, Bechstein WO, Woeste G, Schnitzbauer AA, Ulrich F. The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasis. Surg Today. 2015;45:1527-1534. [PMID: 25563588 DOI: 10.1007/s00595-014-1108-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
237 Hoekstra E, Das AM, Willemsen M, Swets M, Kuppen PJ, van der Woude CJ, Bruno MJ, Shah JP, Ten Hagen TL, Chisholm JD, Kerr WG, Peppelenbosch MP, Fuhler GM. Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation. Oncotarget 2016;7:73525-40. [PMID: 27716613 DOI: 10.18632/oncotarget.12321] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
238 Hayashi M, Inoue Y, Komeda K, Shimizu T, Asakuma M, Hirokawa F, Miyamoto Y, Okuda J, Takeshita A, Shibayama Y. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg. 2010;10:27. [PMID: 20875094 DOI: 10.1186/1471-2482-10-27] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
239 Schnitzbauer AA. A Comparison of Pitfalls after ALPPS Stage 1 or Portal Vein Embolization in Small-for-Size Setting Hepatectomies. Visc Med. 2017;33:435-441. [PMID: 29344517 DOI: 10.1159/000480100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
240 Abrahao ABK, Karim S, Colwell B, Berry S, Biagi J. The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement. Curr Oncol 2017;24:390-400. [PMID: 29270051 DOI: 10.3747/co.24.3757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
241 Kato T, Matsuhashi N, Tomita H, Takahashi T, Iwata Y, Fukada M, Yasufuku I, Suetsugu T, Imai T, Mori R, Imai H, Tanaka Y, Okumura N, Hara A, Yoshida K. MYC Up-regulation Is a Useful Biomarker for Preoperative Neoadjuvant Chemotherapy Combined With Anti-EGFR in Liver Metastasis from Colorectal Cancer. In Vivo 2021;35:203-13. [PMID: 33402467 DOI: 10.21873/invivo.12249] [Reference Citation Analysis]
242 Chua TC, Morris DL. Colorectal liver metastases with extrahepatic disease--a new criteria for oncologic resection? J Gastrointest Cancer. 2012;43:502-504. [PMID: 21494785 DOI: 10.1007/s12029-011-9278-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
243 van Dam RM, Lodewick TM, van den Broek MA, de Jong MC, Greve JW, Jansen RL, Bemelmans MH, Neumann UP, Olde Damink SW, Dejong CH. Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases. HPB (Oxford). 2014;16:550-559. [PMID: 24246003 DOI: 10.1111/hpb.12181] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
244 Homayounfar K, Bleckmann A, Conradi LC, Sprenger T, Beissbarth T, Lorf T, Niessner M, Sahlmann CO, Meller J, Becker H, Liersch T, Ghadimi BM. Bilobar spreading of colorectal liver metastases does not significantly affect survival after R0 resection in the era of interdisciplinary multimodal treatment. Int J Colorectal Dis 2012;27:1359-67. [PMID: 22430890 DOI: 10.1007/s00384-012-1455-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
245 Lim C, Dejong CH, Farges O; e-HPBchir Study Group from the Association de Chirurgie Hépato-Biliaire et de Transplantation (ACHBT) (Association of Hepatobilary and Transplant Surgery). Improving the quality of liver resection: a systematic review and critical analysis of the available prognostic models. HPB (Oxford) 2015;17:209-21. [PMID: 25322917 DOI: 10.1111/hpb.12346] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
246 Link KH, Kornmann M, Staib L, Kreuser ED, Gaus W, Röttinger E, Suhr P, Maulbecker-Armstrong C, Danenberg P, Danenberg K, Schatz M, Sander S, Ji ZL, Li JT, Peng SY, Bittner R, Beger HG, Traub B. Patient-centered developments in colon- and rectal cancer with a multidisciplinary international team: From translational research to national guidelines. World J Gastrointest Surg 2021; 13(12): 1597-1614 [DOI: 10.4240/wjgs.v13.i12.1597] [Reference Citation Analysis]
247 Garlipp B, Gibbs P, Van Hazel GA, Jeyarajah R, Martin RCG, Bruns CJ, Lang H, Manas DM, Ettorre GM, Pardo F, Donckier V, Benckert C, van Gulik TM, Goéré D, Schoen M, Pratschke J, Bechstein WO, de la Cuesta AM, Adeyemi S, Ricke J, Seidensticker M. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial.Br J Surg. 2019;106:1837-1846. [PMID: 31424576 DOI: 10.1002/bjs.11283] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
248 Hofheinz RD, Stintzing S. [Personalized systemic treatment of metastatic colorectal cancer]. Internist (Berl) 2020;61:699-710. [PMID: 32494899 DOI: 10.1007/s00108-020-00808-x] [Reference Citation Analysis]
249 Luu C, Arrington AK, Schoellhammer HF, Singh G, Kim J. Targeted therapies in colorectal cancer: surgical considerations. J Gastrointest Oncol 2013;4:328-36. [PMID: 23997944 DOI: 10.3978/j.issn.2078-6891.2013.032] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
250 Inoue Y, Hiro J, Toiyama Y, Tanaka K, Mohri Y, Kusunoki M. Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer. Oncol Lett 2012;3:363-8. [PMID: 22740912 DOI: 10.3892/ol.2011.508] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
251 Ma LG, Xi HQ, Chen L. Conversion therapy for unresectable gastric cancer. Shijie Huaren Xiaohua Zazhi 2016; 24(4): 528-534 [DOI: 10.11569/wcjd.v24.i4.528] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
252 Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S, Illerhaus G, Königsrainer A, Richter M, Schlitt HJ, Schmoll HJ. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer 2012;12:356. [PMID: 22897915 DOI: 10.1186/1471-2407-12-356] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
253 Primavesi F, Stättner S, Jäger T, Göbel G, Presl J, Tomanová K, Buchner S, Maglione M, Resch T, Hutter J, Öfner D, Dinnewitzer A. Progressive Oncological Surgery Is Associated with Increased Curative Resection Rates and Improved Survival in Metastatic Colorectal Cancer. Cancers (Basel) 2019;11:E218. [PMID: 30769860 DOI: 10.3390/cancers11020218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
254 Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Frébourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease. BMC Med 2012;10:135. [PMID: 23136868 DOI: 10.1186/1741-7015-10-135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
255 Zoratto F, Rossi L, Giordani E, Strudel M, Papa A, Tomao S. From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors. Tumour Biol 2014;35:8471-82. [PMID: 25062724 DOI: 10.1007/s13277-014-2367-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
256 Ikoma N, Raghav K, Chang G. An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surg Oncol Clin N Am. 2017;26:667-687. [PMID: 28923224 DOI: 10.1016/j.soc.2017.05.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
257 Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. JAMA Oncol. 2017;3:e170278. [PMID: 28542671 DOI: 10.1001/jamaoncol.2017.0278] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 15.2] [Reference Citation Analysis]
258 Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Tabernero J, Teh C, Van Cutsem E;  Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17:1225-1239. [PMID: 22962059 DOI: 10.1634/theoncologist.2012-0121] [Cited by in Crossref: 284] [Cited by in F6Publishing: 255] [Article Influence: 28.4] [Reference Citation Analysis]
259 Evrard S. [Colorectal liver metastases: history, sciences and clinical practices]. Bull Cancer 2014;101:373-9. [PMID: 24793630 DOI: 10.1684/bdc.2014.1930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
260 Wang CY, Zhou SC, Li XW, Li BH, Zhang JJ, Ge Z, Zhang Q, Hu JH. Bibliometric analysis of randomized controlled trials of colorectal cancer over the last decade. World J Clin Cases 2020; 8(14): 3021-3030 [PMID: 32775383 DOI: 10.12998/wjcc.v8.i14.3021] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
261 Loupakis F, Stein A, Ychou M, Hermann F, Salud A, Österlund P. A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. Target Oncol 2016;11:293-308. [PMID: 26687849 DOI: 10.1007/s11523-015-0400-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
262 Pan Z, Peng J, Lin J, Chen G, Wu X, Lu Z, Deng Y, Zhao Y, Sui Q, Wan D. Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection? Cancer Commun (Lond) 2018;38:29. [PMID: 29843800 DOI: 10.1186/s40880-018-0298-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
263 Brouquet A, Zimmitti G, Kopetz S, Stift J, Julié C, Lemaistre AI, Agarwal A, Patel V, Benoist S, Nordlinger B, Gandini A, Rivoire M, Stremitzer S, Gruenberger T, Vauthey JN, Maru DM. Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. Cancer 2013;119:2778-88. [PMID: 23868456 DOI: 10.1002/cncr.28097] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
264 Tani K, Shindoh J, Takamoto T, Shibahara J, Nishioka Y, Hashimoto T, Sakamoto Y, Hasegawa K, Makuuchi M, Kokudo N. Kinetic Changes in Liver Parenchyma After Preoperative Chemotherapy for Patients with Colorectal Liver Metastases. J Gastrointest Surg 2017;21:813-21. [PMID: 28083837 DOI: 10.1007/s11605-017-3359-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
265 Lam VW, Laurence JM, Pang T, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. HPB (Oxford). 2014;16:101-108. [PMID: 23509899 DOI: 10.1111/hpb.12083] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
266 Huang X, Zou Y, Lian L, Wu X, He X, He X, Wu X, Huang Y, Lan P. Changes of T cells and cytokines TGF-β1 and IL-10 in mice during liver metastasis of colon carcinoma: implications for liver anti-tumor immunity. J Gastrointest Surg 2013;17:1283-91. [PMID: 23670517 DOI: 10.1007/s11605-013-2194-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
267 Merkel S, Schellerer VS, Wein A, Semrau S, Geppert C, Göhl J, Hohenberger W, Weber K, Grützmann R. The influence of tumour site on prognosis in metastatic colorectal carcinomas with primary tumour resection. Int J Colorectal Dis 2018;33:1215-23. [PMID: 29915904 DOI: 10.1007/s00384-018-3098-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
268 Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 2012;104:1785-95. [PMID: 23197490 DOI: 10.1093/jnci/djs433] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 7.2] [Reference Citation Analysis]
269 Lang H, Gassmann P. Chirurgische Standards und Resektionsausmaß. Viszeralmedizin 2012;28:14-20. [DOI: 10.1159/000336696] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
270 Rees M, Elias D, Coimbra FJ, Orloff SL; Americas Hepato-Pancreato-Biliary Association., Society of Surgical Oncology., Society for Surgery of the Alimentary Tract. Selection for hepatic resection: expert consensus conference. HPB (Oxford) 2013;15:104-5. [PMID: 23297720 DOI: 10.1111/j.1477-2574.2012.00568.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
271 De Greef K, Rolfo C, Russo A, Chapelle T, Bronte G, Passiglia F, Coelho A, Papadimitriou K, Peeters M. Multisciplinary management of patients with liver metastasis from colorectal cancer. World J Gastroenterol 2016; 22(32): 7215-7225 [PMID: 27621569 DOI: 10.3748/wjg.v22.i32.7215] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
272 Han MH, Park YY, Pratap S, Han YD, Cho MS, Hur H, Min BS, Lee KY, Kim NK. Short-term Outcomes After Upfront Chemotherapy Followed by Curative Surgery in Metastatic Colon Cancer: A Comparison With Upfront Surgery Patients. Ann Coloproctol 2019;35:327-34. [PMID: 31937072 DOI: 10.3393/ac.2019.03.04.1] [Reference Citation Analysis]
273 Hoang T, Kim J. Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments. Cancers (Basel) 2020;12:E2663. [PMID: 32961943 DOI: 10.3390/cancers12092663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
274 Ochiai T, Umeki M, Miyake H, Iida T, Okumura M, Ohno K, Sakamoto M, Miyoshi N, Takahashi M, Tsumura H, Tokunaga Y, Naitou H, Fukui T. Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. Oncol Rep 2014;32:887-92. [PMID: 24994673 DOI: 10.3892/or.2014.3299] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
275 Haque SU, Morton D, Welch H. Biologics against cancer-specific receptors - challenges to personalised medicine from early trial results. Curr Opin Pharmacol 2012;12:392-7. [PMID: 22738821 DOI: 10.1016/j.coph.2012.05.003] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
276 Koşaloğlu Z, Zörnig I, Halama N, Kaiser I, Buchhalter I, Grabe N, Eils R, Schlesner M, Califano A, Jäger D. Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases. Oncoimmunology 2016;5:e1213931. [PMID: 27999735 DOI: 10.1080/2162402X.2016.1213931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
277 Cremolini C, Casagrande M, Loupakis F, Aprile G, Bergamo F, Masi G, Moretto R R, Pietrantonio F, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. European Journal of Cancer 2017;73:74-84. [DOI: 10.1016/j.ejca.2016.10.028] [Reference Citation Analysis]
278 Papadimitriou K, Rolfo C, Dewaele E, Van De Wiel M, Van den Brande J, Altintas S, Huizing M, Specenier P, Peeters M. Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer. Curr Treat Options Oncol 2015;16:18. [PMID: 25813037 DOI: 10.1007/s11864-015-0333-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
279 Grundmann RT. Current state of surgical treatment of liver metastases from colorectal cancer. World J Gastrointest Surg 2011; 3(12): 183-196 [PMID: 22224173 DOI: 10.4240/wjgs.v3.i12.183] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
280 Papamichail M, Pizanias M, Heaton ND, M P, M P, Nd H. Minimizing the risk of small-for-size syndrome after liver surgery. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00230-7. [PMID: 34961675 DOI: 10.1016/j.hbpd.2021.12.005] [Reference Citation Analysis]
281 Moehler M, Folprecht G, Heinemann V, Holch JW, Maderer A, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Geißler M, Schulz-Abelius A, Linz B, Bernhard H, Paul A, Schmidtmann I, Potthoff K, Schimanski CC. Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). Int J Cancer 2021. [PMID: 34807464 DOI: 10.1002/ijc.33881] [Reference Citation Analysis]
282 Torzilli G, Vauthey JN, Belghiti J, Makuuchi M, Donadon M, Viganò L, Kokudo N. EWALT: East Meets West in a Multidisciplinary Setting to Improve the Management of Liver Tumors. Liver Cancer 2016;6:13-5. [PMID: 27995083 DOI: 10.1159/000449494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
283 Lordick F, Knödler M, Hacker U, Bartels M. [Neoadjuvant chemotherapy or primary surgery for colorectal liver metastases. Pro adjuvant chemotherapy]. Chirurg 2014;85:11-6. [PMID: 24292192 DOI: 10.1007/s00104-013-2564-2] [Reference Citation Analysis]
284 Juez I, Rubio C, Figueras J. Multidisciplinary approach of colorectal liver metastases. Clin Transl Oncol. 2011;13:721-727. [PMID: 21975333 DOI: 10.1007/s12094-011-0722-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
285 Giuliani J, Bonetti A. The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical Trials. J Gastrointest Cancer 2016;47:341-50. [PMID: 27488729 DOI: 10.1007/s12029-016-9862-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
286 Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, Fisher GA, Jensen RT. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011;146:724-732. [PMID: 21690450 DOI: 10.1001/archsurg.2011.129] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
287 Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol 2022;14:175883592110727. [DOI: 10.1177/17588359211072703] [Reference Citation Analysis]
288 Worni M, Shah KN, Clary BM. Colorectal cancer with potentially resectable hepatic metastases: optimizing treatment. Curr Oncol Rep. 2014;16:407. [PMID: 25129331 DOI: 10.1007/s11912-014-0407-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
289 Sullivan KM, Kozuch PS. Impact of KRAS Mutations on Management of Colorectal Carcinoma. Patholog Res Int. 2011;2011:219309. [PMID: 21437184 DOI: 10.4061/2011/219309] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
290 Cui CH, Huang SX, Qi J, Zhu HJ, Huang ZH, Yu JL. Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis. Oncotarget 2015;6:44005-18. [PMID: 26515604 DOI: 10.18632/oncotarget.5875] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
291 Azizi E, Kittai A, Kozuch P. Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer. Chemother Res Pract 2012;2012:198197. [PMID: 23091721 DOI: 10.1155/2012/198197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]